Joel Lexchin

Q: What Schools Are Affiliated With Joel Lexchin

Joel Lexchin is affiliated with the following schools: York University, University of York, University of Toronto

Joel Lexchin's AcademicInfluence.com Rankings

Joel Lexchin

Philosophy

#6229

World Rank

#9231

Historical Rank

Logic

#3412

World Rank

#4565

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Joel Lexchin Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joel Lexchin is a professor emeritus at the York University Faculty of Health where he taught about pharmaceutical policy, an Associate Professor in the Department of Family and Community Medicine at the University of Toronto, an emergency physician at the Toronto General Hospital and a Fellow in the Canadian Academy of Health Sciences. Lexchin is the author of over 160 peer-reviewed publications.

(See a Problem?)

Joel Lexchin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmaceutical industry sponsorship and research outcome and quality: systematic review (2003) (1957)
Industry sponsorship and research outcome. (2012) (884)
Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review (2010) (477)
Industry sponsorship and research outcome. (2017) (443)
The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States (2008) (440)
The cost of drug development: a systematic review. (2011) (430)
Interactions between physicians and the pharmaceutical industry: what does the literature say? (1993) (291)
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. (2003) (286)
Physician Awareness of Drug Cost: A Systematic Review (2007) (255)
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey (2002) (244)
Pharmaceutical research and development: what do we get for all that money? (2012) (224)
Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence (2004) (189)
The pharmaceutical industry as a medicines provider (2002) (172)
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. (2003) (170)
Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs (2013) (146)
Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications (2012) (140)
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No (2002) (139)
Surrogate outcomes in clinical trials: a cautionary tale. (2013) (112)
Bigger and Better: How Pfizer Redefined Erectile Dysfunction (2006) (109)
What information do physicians receive from pharmaceutical representatives? (1997) (107)
Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States (2013) (104)
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. (2011) (103)
Commercial influence and the content of medical journals (2006) (102)
The effect of generic competition on the price of brand-name drugs. (2004) (100)
Doctors and Detailers: Therapeutic Education or Pharmaceutical Promotion? (1989) (93)
Industry sponsorship and research outcome: systematic review with meta-analysis (2018) (87)
A systematic review of studies comparing health outcomes in Canada and the United States (2007) (86)
Drug withdrawals from the Canadian market for safety reasons, 1963–2004 (2005) (86)
Sponsorship bias in clinical research. (2012) (84)
Physician awareness of diagnostic and nondrug therapeutic costs: A systematic review (2008) (83)
Drug promotion: what we know, what we have yet to learn : reviews of materials in the WHO/HAI database on drug promotion (2004) (79)
Pathways to independence: towards producing and using trustworthy evidence (2019) (74)
Lifestyle drugs: issues for debate. (2001) (66)
Foreign free riders and the high price of US medicines (2005) (64)
Is there still a role for spontaneous reporting of adverse drug reactions? (2006) (64)
Strategies for improving prescribing practice. (1996) (64)
New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? (2012) (64)
Implications of Pharmaceutical Industry Funding on Clinical Research (2005) (54)
Improving the Appropriateness of Physician Prescribing (1998) (53)
A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. (2015) (51)
“Adaptive pathways” to drug authorisation: adapting to industry? (2016) (51)
Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study (2012) (50)
Do drug advertisements in Russian medical journals provide essential information for safe prescribing? (2001) (49)
Clinical trials register (2004) (49)
The effect of early in-hospital medication review on health outcomes: a systematic review. (2015) (46)
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews (2013) (44)
Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations (2006) (44)
Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critique. (2008) (44)
Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change? (2016) (44)
Poor Reporting of Scientific Leadership Information in Clinical Trial Registers (2008) (44)
Medicine reimbursement recommendations in Canada, Australia, and Scotland. (2008) (43)
Drug makers and drug regulators: too close for comfort. A study of the Canadian situation. (1990) (42)
Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. (1994) (41)
Why do cancer drugs get such an easy ride? (2015) (41)
Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies. (2010) (41)
Pharmacovigilance in Europe and North America: divergent approaches. (2012) (37)
'Linkage' pharmaceutical evergreening in Canada and Australia (2007) (37)
Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools (2013) (37)
Financial Conflicts of Interest Checklist 2010 for clinical research studies (2010) (34)
How well do Canadian media outlets convey medical treatment information? (2008) (33)
Medicines Information and the Regulation of the Promotion of Pharmaceuticals (2018) (33)
Effects of restrictive formularies in the ambulatory care setting. (2002) (32)
Financial ties between leaders of influential US professional medical associations and industry: cross sectional study (2020) (32)
Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. (2015) (32)
The danger of imperfect regulation: OxyContin use in the United States and Canada. (2011) (31)
Legislative regulation and ethical governance of medical research in different European Union countries (2013) (31)
Investigator experiences with financial conflicts of interest in clinical trials (2011) (30)
Pharmaceutical Promotion in Canada: Convince Them or Confuse Them (1987) (30)
Pharmaceuticals, Patents, and Politics: Canada and Bill C-22 (1993) (30)
Reporting of Conflicts of Interest in Meta-Analyses of Trials of Pharmacological Treatments (2011) (29)
Indicators for measuring mental health: towards better surveillance. (2009) (28)
Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? (1997) (28)
How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009 (2014) (27)
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts (2019) (27)
The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries (2017) (27)
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs (2014) (27)
Ten Principles for More Conservative, Care-Full Diagnosis (2018) (26)
Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. (2019) (25)
Health Canada's use of its priority review process for new drugs: a cohort study (2015) (25)
Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase (2016) (25)
The miracle of the empty beds: A history of tuberculosis in Canada (1977) (25)
Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis (2018) (24)
Don't bite the hand that feeds you. (1999) (24)
After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. (1997) (24)
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices (2006) (23)
Adverse drug events: counting is not enough, action is needed (2006) (23)
Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here? (2005) (22)
Transparency in drug regulation: Mirage or oasis? (2004) (22)
Notice of compliance with conditions: a policy in limbo. (2007) (22)
Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet (2004) (22)
The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes (2011) (22)
Pharmaceutical Promotion in the Third World (1992) (22)
The Future of Drug Coverage in Canada (2015) (21)
One step forward, one step sideways? Expanding research capacity for neglected diseases (2010) (21)
The Need to Systematically Evaluate Clinical Practice Guidelines (2016) (20)
Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State (2016) (20)
Prescribing and Drug Costs in the Province of Ontario (1992) (20)
Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST (2017) (19)
Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder (2017) (19)
Everyday experiences of implicit rationing: comparing the voices of nurses in California and British Columbia (2001) (19)
Models for financing the regulation of pharmaceutical promotion (2012) (19)
Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study (2020) (18)
Healing an ailing pharmaceutical system: prescription for reform for United States and Canada (2018) (18)
Provision of information on regulatory authorities’ websites (2008) (18)
What do Canadians think about physician-pharmaceutical industry interactions? (2013) (17)
How patient outcomes are reported in drug advertisements. (1999) (17)
International comparison of assessments of pharmaceutical innovation. (2012) (17)
The costs of coronavirus vaccines and their pricing (2021) (16)
Effect of generic drug competition on the price of prescription drugs in Ontario. (1993) (16)
Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis (2018) (16)
A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough (2021) (16)
Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary. (2010) (15)
The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia (2016) (15)
Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south (2011) (15)
Can reporting of adverse drug reactions create safer systems while improving health data? (2015) (14)
Challenging the promotion of antidepressants for nonsevere depression (2019) (14)
Financial costs associated with monopolies on biologic medicines in Australia. (2017) (13)
Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution? (2011) (13)
The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. (2017) (13)
The Pharmaceutical Industry in Contemporary Capitalism (2018) (13)
A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada (2016) (13)
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy. (2005) (13)
The real pushers: A critical analysis of the Canadian drug industry (1984) (13)
The FDA’s new clothes (2015) (12)
Should doctors be prescribing new drugs (2002) (12)
Propofol for sedation (1999) (12)
Adverse Drug Reactions: Review of the Canadian literature. (1991) (12)
How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study (2016) (12)
Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them? (2011) (12)
National Evaluation of Policies on Individual Financial Conflicts of Interest in Canadian Academic Health Science Centers (2008) (12)
Canada and access to medicines in developing countries: intellectual property rights first (2013) (12)
Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study (2019) (12)
A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation. (2014) (12)
Influenza vaccination of health care workers (2013) (12)
Prescribing by canadian general practitioners: review of the english language literature. (1990) (12)
Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion? (1994) (11)
Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada (2014) (11)
Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study (2018) (11)
Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey (2010) (11)
Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons (2016) (11)
Do higher drug costs lead to better health? (2005) (10)
We need to mandate drug cost transparency on electronic medical records (2017) (10)
Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? (2014) (10)
Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. (2009) (10)
Clinical Trials in Canada: Whose Interests are Paramount? (2008) (10)
Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study (2018) (10)
Who Needs Faster Drug Approval Times in Canada: The Public or the Industry? (1994) (9)
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States (2020) (9)
Editorial Are new drugs as good as they claim to be (2004) (9)
From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development. (2014) (9)
Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship. (2013) (9)
Secrecy and the health protection branch. (1998) (9)
Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study (2006) (9)
Patent law (2003) (9)
An International Mapping of Medical Care in Nursing Homes (2019) (9)
A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States ‐ 2007 to 2016 (2020) (9)
Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada (2012) (8)
New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials? (2002) (8)
Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009 (2020) (8)
Pharmaceuticals as a market for "lemons": Theory and practice. (2020) (8)
Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort? (2010) (8)
The Portrayal of the Elderly in Drug Advertisements: A Factor in Inappropriate Prescribing? (1990) (8)
Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals (2014) (8)
Voluntary Self-Regulatory Codes: What Should We Expect? (2003) (8)
Is Australia's National Medicines Policy Failing? the Case of Cox-2 Inhibitors (2007) (7)
Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19 (2020) (7)
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study (2014) (7)
Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study. (2017) (7)
Income class and pharmaceutical expenditure in Canada: 1964-1990. (1996) (7)
Marketing versus evidence-based medicine (2012) (7)
Why are there deadly drugs? (2015) (7)
Physicians and drug companies interact. (1993) (7)
Provincial drug plan officials' views of the Canadian drug safety system. (2013) (7)
The “pharmaceuticalisation” of life (2019) (7)
Health Canada’s Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis (2019) (7)
Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study (2019) (7)
A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. (2006) (7)
Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. (2017) (7)
Does the C in CME stand for “Continuing” or “Commercial”? (2005) (7)
Drugs of Choice: A Formulary for General Practice (1998) (7)
Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic? (2016) (6)
Statistics in drug advertising: what they reveal is suggestive what they hide is vital (2010) (6)
Prescribing to the elderly: a review of the english language canadian literature. (1989) (6)
Canada finally opens up data on new drugs and devices (2019) (6)
Are drugs too expensive in Canada? Yes. (2006) (6)
CJEM and pharmaceutical advertisements: it's time for an end. (2009) (6)
The siren call of new drugs (2003) (6)
Restoring the Bacloville trial: efficacy and harms. (2020) (6)
Hear No Secrets, See No Secrets, Speak No Secrets: Secrecy in the Canadian Drug Approval System (1999) (6)
Drug Pricing in Canada (2015) (6)
Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately? (2017) (6)
The Medical Profession and the Pharmaceutical Industry: An Unhealthy Alliance (1988) (6)
Off-Label Drug Use (2016) (6)
Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence (2018) (6)
Economics and industry do not mean ethical conduct in clinical trials (2013) (6)
Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. (2015) (6)
Direct-To-Consumer Advertising (1999) (6)
Rethinking the numbers on adverse drug reactions. (1999) (6)
Secret safety warnings on medicines: A case study of information access requests (2019) (6)
Drug Approval Times and User Fees (2012) (6)
Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study (2019) (6)
Pharmaceutical promotion in New Zealand. (2010) (5)
The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena. (2007) (5)
Prescribing new drugs. (1993) (5)
A call to mandate patient access to personal primary care medical records across Canada (2018) (5)
Achieving greater independence from commercial influence in research (2021) (5)
Combating corruption in the pharmaceutical arena. (2018) (5)
Drug Promotion in India Since 2000: Problems Remain (2020) (5)
How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study (2020) (4)
Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies. (1990) (4)
Relations with the pharmaceutical industry. (1994) (4)
AT FIRST YOU WILL NOT SUCCEED: NEGOTIATING FOR CARE IN THE CONTEXT OF HEALTH REFORM (2004) (4)
Should the C in CME Stand for Commercial? (2012) (4)
Click, click: the internet and prescription drugs (2000) (4)
Code of marketing practices. Voluntary self-regulation for the Pharmaceutical Manufacturers Association of Canada. (1997) (4)
Agents against pediatric diarrhea. Assessing the information companies supply to Canadian physicians. (1994) (4)
National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. (2016) (4)
New directions in drug approval (2004) (4)
Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant? (2019) (4)
Affordable Biologics for All. (2020) (4)
Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study. (2019) (4)
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study (2020) (4)
Globalization, trade deals and drugs: (2001) (4)
Correction. Health Canada's use of its priority review process for new drugs: a cohort study. (2015) (4)
Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States (2016) (4)
Debating benzodiazepine use. (1995) (4)
Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study (2020) (4)
Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study (2017) (4)
General practice formularies: the way ahead? (1989) (4)
Intellectual property rights and drug prices (1998) (3)
Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19 (2020) (3)
Structure-Function Analysis of Global Pharmaceutical Linkage Regulations (2011) (3)
Withdrawals of drugs for safety reasons: how do regulators decide if they are too unsafe? (2006) (3)
Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis (2022) (3)
Stop the merry-go-round. (2004) (3)
Direct‐to‐consumer advertising policy in Australia: realism in whose interests? (2007) (3)
"Disinformation" from pharmaceutical company representatives. (1990) (3)
Drug safety and Health Canada (2010) (3)
Are academia–pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic? (2020) (3)
Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study (2020) (3)
ADVERTISEMENT SCRUTINY (1987) (3)
Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. (2018) (3)
PMAC code of marketing practices. (1999) (3)
Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study. (2015) (3)
Consequences of direct-to-consumer advertising of prescription drugs. (1997) (3)
Pharmaceutical ads in journals. (1992) (3)
Statistics can affect treatment decisions. (2003) (3)
Use of methylphenidate for attention deficit hyperactivity disorder. (1991) (2)
Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options? (2023) (2)
Educating Health Professionals about Drug and Device Promotion: Authors' Reply (2007) (2)
Can direct-to-consumer advertising of prescription drugs be effectively regulated? (2019) (2)
Canadian status of "drugs to avoid" in 2017: a descriptive analysis. (2018) (2)
Pharmaceutical advertising in medical journals. (1984) (2)
Longer exclusivity does not guarantee better drugs. (2011) (2)
Innovation and off‐label use, the French case and more (2019) (2)
Of Money and Trust in Biomedical Care (2007) (2)
Inaccessibility of drug reports. (2002) (2)
Drug advertising in medical journals (2003) (2)
Pfizer Diflucan Partnership Program (2003) (2)
The marketing of drugs: how drug companies manipulate the prescribing habits of doctors (2006) (2)
New CMAJ policy on competing interests in guidelines needs strengthening (2019) (2)
Progressive licensing of drugs: music or noise? (2008) (2)
The Pharmaceutical Industry and the Canadian Government: Folie à Deux (2017) (2)
After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada (2022) (2)
Antidepressants are not safe during pregnancy and in women of child‐bearing age (2021) (2)
Regulating drugs for effectiveness and safety: a public health perspective. (2007) (2)
Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario (2018) (2)
Is there a bias in industry supported clinical research (1995) (2)
Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care between Patients and Providers (2019) (2)
COVID-19 Vaccine Task Force and Conflicts of Interest. (2022) (2)
Drug prices: How do we get to a better place? (2017) (2)
Time to market for drugs approved in Canada between 2014 and 2018: an observational study (2021) (2)
Why are we still poisoning the elderly so often? (1993) (2)
Journal supplements and evidence-based medicine. (2001) (2)
Rebuttal: are drugs too expensive in Canada? (2006) (2)
Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia (2019) (2)
Appetite stimulant claim deleted from label. (1994) (2)
The “Nuts and Bolts” of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse (2020) (1)
Pharmaceutical Company Payments to Healthcare Professionals and Healthcare Organizations in Canada: An Observational Study (2022) (1)
Economics and industry do not mean ethical conduct in clinical trials (2013) (1)
Medicines Save, Medicines Kill (2017) (1)
Pharmaceutical company advertising in The Lancet (2011) (1)
Key Opinion Leaders and the Control of Knowledge (2020) (1)
Choosing Wisely Canada Needs to Start Helping Doctors to Understand How Commercial Influences Affect Their Prescribing (2019) (1)
Challenging the Corporate Struggle to Rule Our System (2005) (1)
Health Canada's Proposal to Accelerate New Drug Reviews (2020) (1)
Time to Marketing of Generic Drugs After Patent Expiration in Canada (2021) (1)
NSAIDs and peptic ulcer. (1992) (1)
Nonprescription cough and cold remedies. (1990) (1)
Drug advertising in medical journals. Authors' reply (2003) (1)
Marketing before patenting: implications for price controls in Canada (2010) (1)
Double standards: double jeopardy (2000) (1)
Composition of Canadian Pain Society guideline development group? (2018) (1)
Promotion of Medicines in Low- and Middle-Income Countries (2020) (1)
Use of methylphenidate for attention deficit hyperactivity disorder. (1991) (1)
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis (2017) (1)
Pfizer Diflucan Partnership Program. Authors' reply (2003) (1)
Preferred medicines list. (1988) (1)
PAAB: a lesson in self-government. (1991) (1)
Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study (2022) (1)
The Timeliness of New Drug Approvals in Canada: A Rejoinder (1995) (1)
Pharmaceutical innovation: can we live forever? A commentary on Schnittker and Karandinos. (2010) (1)
Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study (2022) (1)
Doctors and Industry Funding of Continuing Medical Education: Guilty as Charged (2008) (1)
Controversial use of bromocriptine. (1996) (1)
USE OF SURROGATE OUTCOMES IN MEDICAL JOURNAL ADVERTISING IN CANADA (2013) (1)
More than the diagnosis. (2009) (1)
Reader Upset at CFPC's Involvement in Prescribing Survey. (1984) (1)
Reducing drug costs. (1989) (1)
Corruption of the Canadian Drug Regulatory System (2020) (1)
Costs of noncompliance disputed. (1996) (1)
Decline in pharmaceutical research. (1984) (1)
$5 per prescription for the treatment of simple, uncomplicated urinary tract infections. (1988) (1)
Pharmaceutical Sales Representatives and Patient Safety (2013) (1)
The management of acute otitis media. (1994) (1)
The relationship between pharmaceutical regulation and inappropriate prescribing: the case of psychotropic drugs in Canada during the 1960s and early 1970s (1998) (1)
Inappropriate prescribing: how much are patients at fault? (1996) (1)
Of Money and Trust in Medical Care Redux (2012) (1)
The International War on Cheap Drugs (2004) (1)
The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946–1990 (2020) (1)
Different conclusions about memantine. (2007) (1)
Clinical Practice Guidelines and Managing Financial Conflicts of Interest (2020) (1)
Réglementation pharmaceutique au Canada et prescription inadéquate de médicaments : le cas des psychotropes dans les années 60 et au début des années 70 (1997) (1)
6. Social Responsibility and Marketing of Drugs in Developing Countries: A Goal or an Oxymoron? (2012) (1)
Drug approval times. (2000) (1)
Editorial: Progressive Licensing of Drugs: Music or Noise? (2008) (1)
P036: A comprehensive quality improvement initiative to prevent falls in the emergency department (2017) (1)
The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system (2019) (1)
It’s Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada" (2020) (1)
Prescription charges and drug utilisation. (1992) (1)
Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here". (2023) (0)
Opioid abuse (2013) (0)
Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know (2019) (0)
Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no. (2011) (0)
Questions about Adderall XR (2006) (0)
International Mapping of Care in Homes. (2019) (0)
Less talk, more action needed to reform IP for all (2022) (0)
Myths and Realities About Why Prescription Drug Prices in the United States Are So High (2017) (0)
Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis. (2021) (0)
ADVERTISING DRUGS TO THE PUBLIC (1989) (0)
Safeguarding the quality of clinical research. (2003) (0)
Hippocrates and Targin (2016) (0)
Plus ça change.... (2000) (0)
The FDA's new clothes The FDA does not protect patients from harmful or ineffective drugs, but approves both (2015) (0)
Diuretic-induced hypokalemia in hypertension. (1985) (0)
Drug promotion. (1987) (0)
Who should fund CME? (2013) (0)
Breastfeeding still the best. (1996) (0)
Industry involvement in clinical practice guidelines (2021) (0)
Debating the use of SMRs. (1994) (0)
Drug regulation: two paradigms in conflict (2018) (0)
Treating hyperkalaemia (2003) (0)
A sorry tale of unnecessary secrecy about medicine safety (2021) (0)
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study (2022) (0)
Prescribing practices. (1994) (0)
Good starter guide to women's health (1997) (0)
Interactions between doctors and pharmaceutical sales representatives. (2001) (0)
Navigating the Evidence: Communicating Canadian Health Policy in the Media (2015) (0)
Millennium Series Millennium Series (2000) (0)
To the editor:1 (2001) (0)
Myths and Realities About Why Prescription Drug Prices in the United States Are So High (2017) (0)
Resources for prevention of cardiovascular disease. (1990) (0)
Formula choices in infants with cow’s milk allergy (2021) (0)
DRUG ECONOMICS IN DEVELOPING COUNTRIES (1989) (0)
Guideline Trustworthiness, Relevance, and Utility Scoring Tool (2018) (0)
Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis (2018) (0)
Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study. (2015) (0)
Prescribing errors (2005) (0)
Editorial. (2018) (0)
Who assigns value in value-based insurance design? (2020) (0)
Priority reviews: innovation and safety (2017) (0)
Drug Ads and Medical Journals. (1976) (0)
Potential therapeutic value of new drugs approved in Australia: a retrospective cohort study. (2023) (0)
Putting a price on drugs. (1997) (0)
Antihypertensive drugs and advertising. (1988) (0)
Esophageal detector devices and children (1999) (0)
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]. (1997) (0)
Time for costly medicine monopolies to go from TPP trade talks (2017) (0)
Anti-counterfeiting trade agreement (ACTA) and access to essential medications: The Canadian perspective (2013) (0)
Treatment of Gaucher's disease. (1993) (0)
Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada. (2023) (0)
Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study (2022) (0)
Cost recovery by Health Canada and drug safety: a time-series analysis. (2018) (0)
Residents and pharmaceutical representatives. (1998) (0)
A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study (2021) (0)
Disclosure at Pfizer Canada. (2002) (0)
Pharmaceutical Industry-Initiated Postapproval Studies-Not Requested by the US FDA, Little Value, and Many Questions. (2019) (0)
What’s Big Pharma Buying When It Gives Money to Your Doctor? | The Tyee (2018) (0)
Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. (2019) (0)
A sample argument. (1991) (0)
COVID-19: still much to learn (2020) (0)
Search Results for: merck (2013) (0)
PRESCRIBING HABITS (1989) (0)
Search Results for: don\'t know what a vaccine adverse reaction is (2013) (0)
Advancing Science in the Service of Humanity Professionalism and Ethical Safeguards (2016) (0)
A hypertensive snow bird (2005) (0)
Health Canada: optimizing transparency and its impact for patients (2021) (0)
' s report Title : A cross-sectional analysis of HIV & hepatitis C clinical trials 2007-2010 : The relationship between industry sponsorship and randomized study design Version : 1 Date : 7 September 2013 (0)
Dextromethorphan is an effective cough suppressant. (2001) (0)
The potential benefits of a national vaccine registry for Canada (2021) (0)
Skilled use of the media by vested interests to promote drugs and other health products (2016) (0)
Too much disclosure of product risks? CBC television, SOGC, and Diane-35. (2003) (0)
Drug not considered a first-line agent. (1998) (0)
Pharmaceutical security for Canada (2022) (0)
DECLARATION OF VESTED INTEREST (1989) (0)
Rushed cancer drug approvals poor deal for all (2015) (0)
Information about a discontinued drug (2008) (0)
The use of sedative-hypnotic drugs in a university teaching hospital. (1990) (0)
Lessons from India and Thailand for Cambodia's future implementation of the TRIPS Agreement for pharmaceutical patents (2023) (0)
Prescribing costs. (1988) (0)
Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study (2022) (0)
Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. (2022) (0)
Health Services and Policy Research in Canada: An Editor's Reflections. (2022) (0)
Commentary: Nesiritide and Lessons Unlearned (2005) (0)
Low back pain. (1995) (0)
Engaging physicians to prescribe more cost-effectively (2020) (0)
LO11: STAR-EM: An innovative summer research program for medical students in an urban Canadian academic emergency department (2020) (0)
Family Physicians and prescribing factors: Comment. (1991) (0)
A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study (2021) (0)
Clinical Trials Are Heavily Influenced by Drug Companies (2011) (0)
prescribing practices * pratiques d ' ordonnance-STRATEGIES FOR IMPROVING PRESCRIBING PRACTICE (2006) (0)
Six Myths About Pharmacare. (2017) (0)
2018 Reviewer Thank You (2019) (0)
Can a health care system change? (1997) (0)
Potential savings from therapeutic substitution of 10 of Canada’s most dispensed prescription drugs (2018) (0)
Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada (2021) (0)
Pharmacists and family physicians. (1986) (0)
Medicines Information and the Regulation of the Promotion of Pharmaceuticals (2018) (0)
Financial conflict of interest among clinical practice guideline-producing organisations. (2020) (0)
Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons (2016) (0)
Guidelines for drug use. (1993) (0)
KOLs and pharma – mutual beneficiaries, but at whose expense? (2017) (0)
Canadian Guide to Prescription Drugs (1990) (0)
Acknowledgement to Referees (2014) (0)
Réfutation : La médecine familiale a-t-elle une obligation professionnelle de jouer un rôle prépondérant dans la recherche sur les médicaments financée par l’industrie pharmaceutique?: NON (2011) (0)
Author ' s response to reviews Title : Sponsor ' s participation in conduct and reporting of industry trials : a descriptive study (2012) (0)
Good introduction to complex topic (1994) (0)
Prix des médicaments. La guerre des Etats-Unis d'Amérique contre les médicaments à prix abordable (2004) (0)
Pharmaceutical Company Sponsorship of Research : A Review (2006) (0)
Letters to the Editor: Doses of selected emergency drugs (1997) (0)
Summary Basis of Decision in context (2005) (0)
Data from: Health Canada’s use of accelerated review pathways and therapeutic innovation, 1995-2016: a cohort study (2018) (0)
Depression in the elderly. (1999) (0)
Re: Response to Light/Lexchin Commentary (2017) (0)
Symposia sponsored by a single pharmaceutical company are less likely to be peer reviewed in the same manner as articles in the parent journal. (1999) (0)
The term cognition-enhancing medications is misleading. (2018) (0)
Deciding whether to use cold remedies: Comment (1991) (0)
Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications (2011) (0)
Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study. (2022) (0)
Evolution of Physician-Industry Relationships in Producing Knowledge of Drug Therapy - Comparison of the United States and Finland (2017) (0)
Misuse of antibiotics in hospitals. (1988) (0)
Antidepressants are not safe during pregnancy and in women of child bearing age. (2021) (0)
Treating attention deficit disorder. (1990) (0)
Copayments and the evidence‐base paradox (2015) (0)
Medications for obesity. (2008) (0)
Research and Development of Drugs for Developing Countries Faces Many Barriers (2011) (0)
Engaging physicians to prescribe more cost-effectively: Blueprint for change. (2020) (0)
Who Should Own the Presses (2006) (0)
Making Evidence Matter in Canadian Health Policy (2014) (0)
Complete dissociation from the health care and pharmaceutical industry. (2015) (0)
Introducing a new drug: an objection. (1988) (0)
National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study (2022) (0)
Payment equity for prescription drugs. (1996) (0)
Ban drug advertisements. (2011) (0)
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. (2017) (0)
Information and promotional strategies by pharmaceutical companies for clinicians (2019) (0)
Diuretic-induced hypokalemia in hypertension. (1985) (0)
Le JCMU et les publicités pharmaceutiques : il est temps d’en finir (2009) (0)
Inciter les médecins à prescrire en se souciant davantage des coûts: Stratégie de changement (2020) (0)
Sécurité d’approvisionnement pharmaceutique au Canada (2022) (0)

This paper list is powered by the following services:

Other Resources About Joel Lexchin

en.wikipedia.org

What Schools Are Affiliated With Joel Lexchin?

Joel Lexchin is affiliated with the following schools: